• Continued strong sales momentum for MetaXplore in Australia and the UK
• Landmark GI study results from over 4,600 patients with 71.4% identifying actionable results
• MetaPanel adoption continues to build in Australia with breakthrough results revealing pathogens in 20% of patients

Microba Life Sciences Limited (ASX: MAP) reported its Q4 FY25 results, highlighting continued growth and clinical adoption of its testing products in Australia and the United Kingdom. In Australia, the company saw a record quarter for its MetaXplore test, with 3,451 tests sold, up 88% year-over-year. This growth was underpinned by a continued increase in the number of ordering clinicians, which reached 790, up 89% year-over-year. The company also reported landmark GI study results from over 4,600 patients, with 71.4% identifying actionable results. In the UK, the company achieved full market access at the end of May 2025, with June delivering a record month. MetaXplore test sales in the UK grew 74% quarter-over-quarter, and now represent 66% of GI tests sold in the UK business. The company's MetaPanel product also continued to gain traction in Australia, with 266 tests sold, up 85% year-over-year. A study on the MetaPanel product delivered breakthrough results, revealing pathogens in 20% of patients. Overall, the company reported Q4 revenue of $15.67 million, up 30% year-over-year, in line with previous guidance. The company's strategic transition towards its core diagnostics business and away from legacy products and services is progressing well.